IDEAYA Biosciences (IDYA)

Executive Summary

IDEAYA Biosciences is a clinical-stage precision oncology company pioneering synthetic lethality approaches to develop targeted therapies for genomically defined patient populations. The company's lead asset, darovasertib (a PKC inhibitor), is advancing in a Phase 3 trial for uveal melanoma (UM), a disease with high unmet need, following promising Phase 2 data. IDEAYA also has a broad pipeline of early-to-mid-stage programs targeting solid tumors, including IDE397 (MAT2A inhibitor) in MTAP-deleted cancers, IDE196 (PKC inhibitor) in combination with MEK/RAF inhibitors for UM, and a novel DLL3-targeted bispecific antibody-drug conjugate (IDE849) in small-cell lung cancer. The company's strategy emphasizes biomarker-driven patient selection and rational combinations to maximize therapeutic index. IDEAYA benefits from multiple partnerships, including collaborations with GSK on a Phase 1/2 trial of GSK4418959 plus a PD-1 inhibitor in colorectal cancer, and with Merck on pembrolizumab combinations. Near-term value drivers include data readouts from the ongoing Phase 1/2 GSK4418959 trial and updates from the Phase 3 darovasertib study. However, the pipeline remains largely early-stage, with significant regulatory and clinical risk. The company's cash position and recent capital raise support operations into 2027, providing a runway to generate key proof-of-concept data. Overall, IDEAYA represents a high-risk, high-reward opportunity in the precision oncology space, with conviction supported by its innovative synthetic lethality platform and strong scientific rationale.

Upcoming Catalysts (preview)

• Q3 2026GSK4418959 + PD-1 inhibitor Phase 1/2 data in colorectal and solid tumors35% success
• Q4 2026Darovasertib Phase 3 uveal melanoma trial enrollment completion or interim analysis60% success
• Q2 2027IDE196 + binimetinib + crizotinib Phase 1/2 data update in metastatic uveal melanoma45% success